Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

Regeneron and Sanofi’s PD-1 inhibitor Libtayo will be tested in tandem with a cancer vaccine developed by BioNTech in melanoma in people who have failed treatment with other checkpoint inhibitors.

Jan. 28, 2025 — A team of stem cell scientists have successfully used embryonic stem cell engineering to create a bi-paternal mouse -- a mouse with two male parents -- that lived until adulthood ...

After hours: 11 March at 7:13:29 pm GMT-4 Loading Chart for REGN ...